Home / Resource Library / Five-Year Analysis of the JULIET Trial of Tisagenlecleucel in Patients With Relapsed/Refractory Large B-Cell Lymphoma

Five-Year Analysis of the JULIET Trial of Tisagenlecleucel in Patients With Relapsed/Refractory Large B-Cell Lymphoma

long term results of a study investigating CAR-T Tisagenlecleucel for treatment of relapsed DLBCL.